These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34516238)

  • 21. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 22. Aducanumab and Accelerated Approval: Where Do We Go From Here?
    Kesselheim AS
    Clin Pharmacol Ther; 2022 Apr; 111(4):726-727. PubMed ID: 35174494
    [No Abstract]   [Full Text] [Related]  

  • 23. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 24. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 26. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

  • 27. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 29. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
    Yuksel JM; Noviasky J; Britton S
    Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
    [No Abstract]   [Full Text] [Related]  

  • 30. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    Emanuel EJ
    JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
    [No Abstract]   [Full Text] [Related]  

  • 31. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 32. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 33. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions?
    Burroughs AW; Krain LP
    AMA J Ethics; 2023 Oct; 25(10):E777-782. PubMed ID: 37801063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
    Crosson FJ; Covinsky K; Redberg RF
    JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
    Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
    Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update: FDA approval of Biogen's aducanumab.
    Hollmann P
    Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
    [No Abstract]   [Full Text] [Related]  

  • 38. Of education and public policy: Aducanumab.
    Lundebjerg NE; Hollmann PA; Supiano MA
    J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
    [No Abstract]   [Full Text] [Related]  

  • 39. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 40. Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
    Dyer O
    BMJ; 2024 Feb; 384():q281. PubMed ID: 38307520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.